The granzyme B inhibitor, PI-9, is differentially expressed during placental development and up-regulated in hydatidiform moles.
The intracellular serpin Proteinase Inhibitor-9 (PI-9) is a potent inhibitor of the cytotoxic lymphocyte (CL) proteinase granzyme B, a major effector molecule used by CLs to induce target cell apoptosis. PI-9 is produced by CLs to protect against mis-directed granzyme B. However, PI-9 expression has also been reported in immune privileged tissues. In the present study, cell-specific expression of PI-9 in placental tissue of various gestational ages was examined by immunohistochemistry. PI-9 is highly expressed by the extravillous trophoblasts that have invaded the decidua, and this high expression is maintained throughout pregnancy. Similar levels were also observed in proliferative villous cytotrophoblasts. Syncytial trophoblasts generally do not produce PI-9 to a significant level until the last few weeks of pregnancy. The villous stroma contains mixed populations of PI-9 positive and negative cells throughout pregnancy, with highest expression during the second trimester. Compared to first trimester placentas, syncytial trophoblasts of partial and complete hydatidiform moles showed marked up-regulation of PI-9. Examination of choriocarcinoma cell lines also demonstrated a very high level of PI-9 is produced by these cells, which may provide protection from granzyme B-mediated apoptosis. The cell-specific expression of PI-9 in the placenta is consistent with a function in the maintenance of immune privilege, and it is proposed that up-regulated expression of PI-9 in gestational trophoblastic diseases contributes to disease pathogenesis via immune evasion.
Buzza
M S
MS
Department of Biochemistry and Molecular Biology, Monash University, Australia.
Hosking
P
P
Bird
P I
PI
D002277:Carcinoma / Q000378:metabolism; D002460:Cell Line; D005260:Female; D018507:Gene Expression Regulation, Developmental; D015972:Gene Expression Regulation, Neoplastic; D053804:Granzymes; D006801:Humans; D006828:Hydatidiform Mole / Q000196:embryology / Q000378:metabolism* / Q000473:pathology; D007150:Immunohistochemistry; D009035:Mothers; D009363:Neoplasm Proteins / Q000378:metabolism*; D010920:Placenta / Q000378:metabolism / Q000473:pathology; D010929:Placentation; D011247:Pregnancy; D012697:Serine Endopeptidases / Q000378:metabolism*; D015842:Serine Proteinase Inhibitors / Q000378:metabolism*; D015843:Serpins / Q000378:metabolism*; D015854:Up-Regulation
D009363:Neoplasm Proteins; C476825:SERPINA9 protein, human; D015842:Serine Proteinase Inhibitors; D015843:Serpins; C509213:GZMB protein, human; D053804:Granzymes; D012697:Serine Endopeptidases